Recent advancements in molecular imaging, particularly with Positron Emission Tomography (PET) using radiolabelled Prostate‐Specific Membrane Antigen (PSMA) tracers, have shown significant improvements in enhancing prostate cancer detection. This evidence concerns the gene FOLH1 and prostate carcinoma.